May 2024 in “Drugs & Therapy Perspectives” New treatments like JAK inhibitors offer hope for better alopecia areata management.
June 2025 in “British Journal of Dermatology” Irish dermatologists urgently need guidelines for using JAK inhibitors in treating alopecia areata.
September 2014 in “SciBX” JAK inhibitors may help treat alopecia areata and promote hair regrowth.
4 citations
,
December 2024 in “JAAD Case Reports” Nirogacestat can cause severe skin issues like hidradenitis suppurativa.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
49 citations
,
June 1998 in “Journal of Endocrinological Investigation” Cyproterone acetate plus ethinyl estradiol is generally more effective in treating hirsutism, but consider side effects and patient characteristics.
June 2026 in “Frontiers in Immunology” Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.
October 2008 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” 5-alpha reductase inhibitors do not increase hip fracture risk.
February 2025 in “Skin Appendage Disorders” Upadacitinib helps most people with alopecia regrow hair quickly and is generally safe.
13 citations
,
January 2017 in “Chemical & Pharmaceutical Bulletin” Certain compounds, especially those with a propionic substituent, could potentially be new treatments for hair loss and similar disorders.
November 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may reduce depression in people with alopecia areata.
56 citations
,
January 2019 in “Lancet” JAK inhibitors help regrow hair in alopecia areata patients, improving their quality of life.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
September 2022 in “Hair transplant forum international” JAK inhibitors like baricitinib are a new FDA-approved treatment for alopecia areata, but safety data is incomplete.
November 2023 in “Dermatologica sinica/Zhōnghuá pífūkē yīxué zázhì” Upadacitinib helped regrow hair in a severe alopecia areata patient but stopping treatment caused hair loss to return.
20 citations
,
February 2002 in “Expert Opinion on Therapeutic Patents” New research is needed to create better drugs that block the enzyme responsible for conditions like male baldness and prostate enlargement.
4 citations
,
August 2021 in “Annals of Translational Medicine” Dihydroartemisinin helps reduce prostate enlargement in rats by stopping the growth of prostate cells.
38 citations
,
October 1996 in “Dermatologic Clinics” Certain hormone treatments can improve acne and related conditions in women.
4 citations
,
July 1983 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” Certain hormones can reduce skin oil and hair growth, potentially helping treat acne and excessive hair in women.
15 citations
,
December 2019 in “European Journal of Dermatology” Low-dose tofacitinib is effective and cheaper for severe alopecia areata.
September 2023 in “JAAD case reports” A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
August 2022 in “Journal of Investigative Dermatology” Baricitinib reduces inflammation and mitochondrial damage in skin cells.
7 citations
,
March 2021 in “Molecular Medicine Reports” A mix of specific inhibitors and a growth factor helps keep hair growth cells from losing their properties in the lab.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
153 citations
,
November 2004 in “Current Medicinal Chemistry” The document concludes that Catalyst software is effective for drug design, identifying potent compounds for various medical conditions.
70 citations
,
April 2016 in “Experimental Dermatology” A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
April 2011 in “Global journal of health science” Aldactone effectively reduces hair thickness in women with excessive hair growth, both alone and with other treatments.
2 citations
,
November 2021 in “ACG Case Reports Journal” Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
March 2025 in “International Journal For Multidisciplinary Research” Computational techniques can improve drug development for treating certain conditions.